HF
GLUE icon

HRT Financial’s Monte Rosa Therapeutics GLUE Stock Holding History

HRT Financial’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,911
Closed -$206K – 2696
2024
Q3 		$206K Buy
+38,911
New +$196K ﹤0.01% 1963
2024
Q1 		– Sell
-63,204
Closed -$357K – 2590
2023
Q4 		$357K Buy
63,204
+52,510
+491% +$206K ﹤0.01% 1543
2023
Q3 		$51K Buy
+10,694
New +$68.8K ﹤0.01% 2001
2022
Q4 		– Sell
-85,798
Closed -$700K – 2707
2022
Q3 		$700K Buy
+85,798
New +$788K 0.01% 1237

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial's GLUE Position: Q4 2024 in Review

HRT Financial sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 38,911 shares — an estimated $206K sold.

HRT Financial first reported a position in GLUE in Q3 2022 and held it in 4 quarters. The position peaked at $700K in Q3 2022. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • HRT Financial reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • HRT Financial sold 38,911 Monte Rosa Therapeutics shares in Q4 2024, an estimated $206K.
  • HRT Financial first reported a position in Monte Rosa Therapeutics in Q3 2022 and held it in 4 quarters.
  • HRT Financial's Monte Rosa Therapeutics position peaked at $700K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.